nodes	percent_of_prediction	percent_of_DWPC	metapath
Oritavancin—Infusion site reaction—Cladribine—multiple sclerosis	0.0881	0.0881	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Fingolimod—multiple sclerosis	0.0157	0.0157	CcSEcCtD
Oritavancin—Extravasation—Cladribine—multiple sclerosis	0.0156	0.0156	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Fingolimod—multiple sclerosis	0.0154	0.0154	CcSEcCtD
Oritavancin—Cellulitis—Cladribine—multiple sclerosis	0.015	0.015	CcSEcCtD
Oritavancin—Hyperuricaemia—Cladribine—multiple sclerosis	0.0147	0.0147	CcSEcCtD
Oritavancin—Blood bilirubin increased—Cladribine—multiple sclerosis	0.0144	0.0144	CcSEcCtD
Oritavancin—Allergic cutaneous angiitis—Methotrexate—multiple sclerosis	0.014	0.014	CcSEcCtD
Oritavancin—Blood uric acid increased—Cladribine—multiple sclerosis	0.0139	0.0139	CcSEcCtD
Oritavancin—Infestation NOS—Fingolimod—multiple sclerosis	0.0135	0.0135	CcSEcCtD
Oritavancin—Infestation—Fingolimod—multiple sclerosis	0.0135	0.0135	CcSEcCtD
Oritavancin—Wheezing—Cladribine—multiple sclerosis	0.0132	0.0132	CcSEcCtD
Oritavancin—Connective tissue disorder—Fingolimod—multiple sclerosis	0.0119	0.0119	CcSEcCtD
Oritavancin—Cardiac disorder—Fingolimod—multiple sclerosis	0.0112	0.0112	CcSEcCtD
Oritavancin—Mediastinal disorder—Fingolimod—multiple sclerosis	0.0109	0.0109	CcSEcCtD
Oritavancin—Extravasation—Mitoxantrone—multiple sclerosis	0.0103	0.0103	CcSEcCtD
Oritavancin—Hyperuricaemia—Mitoxantrone—multiple sclerosis	0.00966	0.00966	CcSEcCtD
Oritavancin—Blood bilirubin increased—Mitoxantrone—multiple sclerosis	0.00947	0.00947	CcSEcCtD
Oritavancin—Abscess—Prednisolone—multiple sclerosis	0.00929	0.00929	CcSEcCtD
Oritavancin—Blood uric acid increased—Mitoxantrone—multiple sclerosis	0.00912	0.00912	CcSEcCtD
Oritavancin—Leukocytoclastic vasculitis—Methotrexate—multiple sclerosis	0.0091	0.0091	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Fingolimod—multiple sclerosis	0.00889	0.00889	CcSEcCtD
Oritavancin—Abscess—Triamcinolone—multiple sclerosis	0.00854	0.00854	CcSEcCtD
Oritavancin—Abscess—Methylprednisolone—multiple sclerosis	0.00852	0.00852	CcSEcCtD
Oritavancin—Infection—Fingolimod—multiple sclerosis	0.00852	0.00852	CcSEcCtD
Oritavancin—Eosinophilia—Cladribine—multiple sclerosis	0.00847	0.00847	CcSEcCtD
Oritavancin—Nervous system disorder—Fingolimod—multiple sclerosis	0.00841	0.00841	CcSEcCtD
Oritavancin—Skin disorder—Fingolimod—multiple sclerosis	0.00833	0.00833	CcSEcCtD
Oritavancin—Abscess—Betamethasone—multiple sclerosis	0.00775	0.00775	CcSEcCtD
Oritavancin—Abscess—Dexamethasone—multiple sclerosis	0.00775	0.00775	CcSEcCtD
Oritavancin—Infestation NOS—Cladribine—multiple sclerosis	0.00762	0.00762	CcSEcCtD
Oritavancin—Infestation—Cladribine—multiple sclerosis	0.00762	0.00762	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.00741	0.00741	CcSEcCtD
Oritavancin—Extravasation—Dexamethasone—multiple sclerosis	0.00703	0.00703	CcSEcCtD
Oritavancin—Extravasation—Betamethasone—multiple sclerosis	0.00703	0.00703	CcSEcCtD
Oritavancin—Abscess—Prednisone—multiple sclerosis	0.00675	0.00675	CcSEcCtD
Oritavancin—Oedema peripheral—Cladribine—multiple sclerosis	0.00674	0.00674	CcSEcCtD
Oritavancin—Connective tissue disorder—Cladribine—multiple sclerosis	0.00673	0.00673	CcSEcCtD
Oritavancin—Wheezing—Triamcinolone—multiple sclerosis	0.00656	0.00656	CcSEcCtD
Oritavancin—Erythema multiforme—Cladribine—multiple sclerosis	0.00647	0.00647	CcSEcCtD
Oritavancin—Cardiac disorder—Cladribine—multiple sclerosis	0.00635	0.00635	CcSEcCtD
Oritavancin—Infestation—Azathioprine—multiple sclerosis	0.0062	0.0062	CcSEcCtD
Oritavancin—Infestation NOS—Azathioprine—multiple sclerosis	0.0062	0.0062	CcSEcCtD
Oritavancin—Immune system disorder—Cladribine—multiple sclerosis	0.00618	0.00618	CcSEcCtD
Oritavancin—Mediastinal disorder—Cladribine—multiple sclerosis	0.00617	0.00617	CcSEcCtD
Oritavancin—Pruritus—Fingolimod—multiple sclerosis	0.00607	0.00607	CcSEcCtD
Oritavancin—Malnutrition—Cladribine—multiple sclerosis	0.00596	0.00596	CcSEcCtD
Oritavancin—Diarrhoea—Fingolimod—multiple sclerosis	0.00587	0.00587	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Mitoxantrone—multiple sclerosis	0.00586	0.00586	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Mitoxantrone—multiple sclerosis	0.00574	0.00574	CcSEcCtD
Oritavancin—Dizziness—Fingolimod—multiple sclerosis	0.00567	0.00567	CcSEcCtD
Oritavancin—Abscess—Methotrexate—multiple sclerosis	0.00564	0.00564	CcSEcCtD
Oritavancin—Anaemia—Cladribine—multiple sclerosis	0.00551	0.00551	CcSEcCtD
Oritavancin—Headache—Fingolimod—multiple sclerosis	0.00537	0.00537	CcSEcCtD
Oritavancin—Erythema multiforme—Azathioprine—multiple sclerosis	0.00526	0.00526	CcSEcCtD
Oritavancin—Extravasation—Methotrexate—multiple sclerosis	0.00512	0.00512	CcSEcCtD
Oritavancin—Myalgia—Cladribine—multiple sclerosis	0.00507	0.00507	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.00504	0.00504	CcSEcCtD
Oritavancin—Immune system disorder—Azathioprine—multiple sclerosis	0.00503	0.00503	CcSEcCtD
Oritavancin—Mediastinal disorder—Azathioprine—multiple sclerosis	0.00502	0.00502	CcSEcCtD
Oritavancin—Infection—Cladribine—multiple sclerosis	0.00483	0.00483	CcSEcCtD
Oritavancin—Hyperuricaemia—Methotrexate—multiple sclerosis	0.00481	0.00481	CcSEcCtD
Oritavancin—Nervous system disorder—Cladribine—multiple sclerosis	0.00477	0.00477	CcSEcCtD
Oritavancin—Tachycardia—Cladribine—multiple sclerosis	0.00475	0.00475	CcSEcCtD
Oritavancin—Skin disorder—Cladribine—multiple sclerosis	0.00472	0.00472	CcSEcCtD
Oritavancin—Blood uric acid increased—Methotrexate—multiple sclerosis	0.00455	0.00455	CcSEcCtD
Oritavancin—Anaemia—Azathioprine—multiple sclerosis	0.00448	0.00448	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Cladribine—multiple sclerosis	0.00443	0.00443	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Methylprednisolone—multiple sclerosis	0.00432	0.00432	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.0042	0.0042	CcSEcCtD
Oritavancin—Bronchospasm—Methylprednisolone—multiple sclerosis	0.00416	0.00416	CcSEcCtD
Oritavancin—Myalgia—Azathioprine—multiple sclerosis	0.00412	0.00412	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.0041	0.0041	CcSEcCtD
Oritavancin—Infection—Azathioprine—multiple sclerosis	0.00393	0.00393	CcSEcCtD
Oritavancin—Urticaria—Cladribine—multiple sclerosis	0.00386	0.00386	CcSEcCtD
Oritavancin—Skin disorder—Azathioprine—multiple sclerosis	0.00384	0.00384	CcSEcCtD
Oritavancin—Infestation NOS—Methylprednisolone—multiple sclerosis	0.00377	0.00377	CcSEcCtD
Oritavancin—Infestation—Methylprednisolone—multiple sclerosis	0.00377	0.00377	CcSEcCtD
Oritavancin—Anaemia—Mitoxantrone—multiple sclerosis	0.00362	0.00362	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Azathioprine—multiple sclerosis	0.0036	0.0036	CcSEcCtD
Oritavancin—Hypersensitivity—Cladribine—multiple sclerosis	0.00358	0.00358	CcSEcCtD
Oritavancin—Pruritus—Cladribine—multiple sclerosis	0.00344	0.00344	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Prednisone—multiple sclerosis	0.00342	0.00342	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.00341	0.00341	CcSEcCtD
Oritavancin—Myalgia—Mitoxantrone—multiple sclerosis	0.00333	0.00333	CcSEcCtD
Oritavancin—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.00333	0.00333	CcSEcCtD
Oritavancin—Diarrhoea—Cladribine—multiple sclerosis	0.00333	0.00333	CcSEcCtD
Oritavancin—Dizziness—Cladribine—multiple sclerosis	0.00322	0.00322	CcSEcCtD
Oritavancin—Infection—Mitoxantrone—multiple sclerosis	0.00318	0.00318	CcSEcCtD
Oritavancin—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.00314	0.00314	CcSEcCtD
Oritavancin—Tachycardia—Mitoxantrone—multiple sclerosis	0.00312	0.00312	CcSEcCtD
Oritavancin—Skin disorder—Mitoxantrone—multiple sclerosis	0.0031	0.0031	CcSEcCtD
Oritavancin—Vomiting—Cladribine—multiple sclerosis	0.00309	0.00309	CcSEcCtD
Oritavancin—Rash—Cladribine—multiple sclerosis	0.00307	0.00307	CcSEcCtD
Oritavancin—Dermatitis—Cladribine—multiple sclerosis	0.00306	0.00306	CcSEcCtD
Oritavancin—Immune system disorder—Methylprednisolone—multiple sclerosis	0.00306	0.00306	CcSEcCtD
Oritavancin—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.00305	0.00305	CcSEcCtD
Oritavancin—Headache—Cladribine—multiple sclerosis	0.00305	0.00305	CcSEcCtD
Oritavancin—Malnutrition—Methylprednisolone—multiple sclerosis	0.00295	0.00295	CcSEcCtD
Oritavancin—Angioedema—Prednisolone—multiple sclerosis	0.00294	0.00294	CcSEcCtD
Oritavancin—Hypersensitivity—Azathioprine—multiple sclerosis	0.00291	0.00291	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.00291	0.00291	CcSEcCtD
Oritavancin—Nausea—Cladribine—multiple sclerosis	0.00289	0.00289	CcSEcCtD
Oritavancin—Eosinophilia—Methotrexate—multiple sclerosis	0.00277	0.00277	CcSEcCtD
Oritavancin—Diarrhoea—Azathioprine—multiple sclerosis	0.00271	0.00271	CcSEcCtD
Oritavancin—Angioedema—Triamcinolone—multiple sclerosis	0.0027	0.0027	CcSEcCtD
Oritavancin—Angioedema—Methylprednisolone—multiple sclerosis	0.00269	0.00269	CcSEcCtD
Oritavancin—Connective tissue disorder—Prednisone—multiple sclerosis	0.00264	0.00264	CcSEcCtD
Oritavancin—Dizziness—Azathioprine—multiple sclerosis	0.00261	0.00261	CcSEcCtD
Oritavancin—Tachycardia—Prednisolone—multiple sclerosis	0.00256	0.00256	CcSEcCtD
Oritavancin—Urticaria—Mitoxantrone—multiple sclerosis	0.00254	0.00254	CcSEcCtD
Oritavancin—Myalgia—Triamcinolone—multiple sclerosis	0.00252	0.00252	CcSEcCtD
Oritavancin—Vomiting—Azathioprine—multiple sclerosis	0.00251	0.00251	CcSEcCtD
Oritavancin—Myalgia—Methylprednisolone—multiple sclerosis	0.00251	0.00251	CcSEcCtD
Oritavancin—Infestation—Methotrexate—multiple sclerosis	0.0025	0.0025	CcSEcCtD
Oritavancin—Infestation NOS—Methotrexate—multiple sclerosis	0.0025	0.0025	CcSEcCtD
Oritavancin—Rash—Azathioprine—multiple sclerosis	0.00249	0.00249	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.00249	0.00249	CcSEcCtD
Oritavancin—Dermatitis—Azathioprine—multiple sclerosis	0.00249	0.00249	CcSEcCtD
Oritavancin—Headache—Azathioprine—multiple sclerosis	0.00248	0.00248	CcSEcCtD
Oritavancin—Angioedema—Dexamethasone—multiple sclerosis	0.00245	0.00245	CcSEcCtD
Oritavancin—Angioedema—Betamethasone—multiple sclerosis	0.00245	0.00245	CcSEcCtD
Oritavancin—Immune system disorder—Prednisone—multiple sclerosis	0.00242	0.00242	CcSEcCtD
Oritavancin—Infection—Triamcinolone—multiple sclerosis	0.0024	0.0024	CcSEcCtD
Oritavancin—Infection—Methylprednisolone—multiple sclerosis	0.00239	0.00239	CcSEcCtD
Oritavancin—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.00236	0.00236	CcSEcCtD
Oritavancin—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.00236	0.00236	CcSEcCtD
Oritavancin—Tachycardia—Triamcinolone—multiple sclerosis	0.00235	0.00235	CcSEcCtD
Oritavancin—Nausea—Azathioprine—multiple sclerosis	0.00235	0.00235	CcSEcCtD
Oritavancin—Tachycardia—Methylprednisolone—multiple sclerosis	0.00235	0.00235	CcSEcCtD
Oritavancin—Skin disorder—Methylprednisolone—multiple sclerosis	0.00234	0.00234	CcSEcCtD
Oritavancin—Malnutrition—Prednisone—multiple sclerosis	0.00233	0.00233	CcSEcCtD
Oritavancin—Myalgia—Betamethasone—multiple sclerosis	0.00228	0.00228	CcSEcCtD
Oritavancin—Myalgia—Dexamethasone—multiple sclerosis	0.00228	0.00228	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.0022	0.0022	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.00219	0.00219	CcSEcCtD
Oritavancin—Diarrhoea—Mitoxantrone—multiple sclerosis	0.00219	0.00219	CcSEcCtD
Oritavancin—Infection—Dexamethasone—multiple sclerosis	0.00217	0.00217	CcSEcCtD
Oritavancin—Infection—Betamethasone—multiple sclerosis	0.00217	0.00217	CcSEcCtD
Oritavancin—Anaemia—Prednisone—multiple sclerosis	0.00216	0.00216	CcSEcCtD
Oritavancin—Nervous system disorder—Dexamethasone—multiple sclerosis	0.00215	0.00215	CcSEcCtD
Oritavancin—Nervous system disorder—Betamethasone—multiple sclerosis	0.00215	0.00215	CcSEcCtD
Oritavancin—Tachycardia—Dexamethasone—multiple sclerosis	0.00214	0.00214	CcSEcCtD
Oritavancin—Tachycardia—Betamethasone—multiple sclerosis	0.00214	0.00214	CcSEcCtD
Oritavancin—Angioedema—Prednisone—multiple sclerosis	0.00213	0.00213	CcSEcCtD
Oritavancin—Erythema multiforme—Methotrexate—multiple sclerosis	0.00212	0.00212	CcSEcCtD
Oritavancin—Urticaria—Prednisolone—multiple sclerosis	0.00208	0.00208	CcSEcCtD
Oritavancin—Cardiac disorder—Methotrexate—multiple sclerosis	0.00208	0.00208	CcSEcCtD
Oritavancin—Vomiting—Mitoxantrone—multiple sclerosis	0.00203	0.00203	CcSEcCtD
Oritavancin—Immune system disorder—Methotrexate—multiple sclerosis	0.00202	0.00202	CcSEcCtD
Oritavancin—Mediastinal disorder—Methotrexate—multiple sclerosis	0.00202	0.00202	CcSEcCtD
Oritavancin—Rash—Mitoxantrone—multiple sclerosis	0.00202	0.00202	CcSEcCtD
Oritavancin—Dermatitis—Mitoxantrone—multiple sclerosis	0.00201	0.00201	CcSEcCtD
Oritavancin—Headache—Mitoxantrone—multiple sclerosis	0.002	0.002	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.00199	0.00199	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.00199	0.00199	CcSEcCtD
Oritavancin—Myalgia—Prednisone—multiple sclerosis	0.00199	0.00199	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.00197	0.00197	CcSEcCtD
Oritavancin—Malnutrition—Methotrexate—multiple sclerosis	0.00195	0.00195	CcSEcCtD
Oritavancin—Hypersensitivity—Prednisolone—multiple sclerosis	0.00193	0.00193	CcSEcCtD
Oritavancin—Urticaria—Triamcinolone—multiple sclerosis	0.00192	0.00192	CcSEcCtD
Oritavancin—Urticaria—Methylprednisolone—multiple sclerosis	0.00191	0.00191	CcSEcCtD
Oritavancin—Nausea—Mitoxantrone—multiple sclerosis	0.0019	0.0019	CcSEcCtD
Oritavancin—Infection—Prednisone—multiple sclerosis	0.00189	0.00189	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.00189	0.00189	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.00189	0.00189	CcSEcCtD
Oritavancin—Nervous system disorder—Prednisone—multiple sclerosis	0.00187	0.00187	CcSEcCtD
Oritavancin—Tachycardia—Prednisone—multiple sclerosis	0.00186	0.00186	CcSEcCtD
Oritavancin—Skin disorder—Prednisone—multiple sclerosis	0.00185	0.00185	CcSEcCtD
Oritavancin—Anaemia—Methotrexate—multiple sclerosis	0.0018	0.0018	CcSEcCtD
Oritavancin—Hypersensitivity—Triamcinolone—multiple sclerosis	0.00178	0.00178	CcSEcCtD
Oritavancin—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.00177	0.00177	CcSEcCtD
Oritavancin—Urticaria—Dexamethasone—multiple sclerosis	0.00174	0.00174	CcSEcCtD
Oritavancin—Urticaria—Betamethasone—multiple sclerosis	0.00174	0.00174	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.00174	0.00174	CcSEcCtD
Oritavancin—Dizziness—Prednisolone—multiple sclerosis	0.00173	0.00173	CcSEcCtD
Oritavancin—Pruritus—Triamcinolone—multiple sclerosis	0.00171	0.00171	CcSEcCtD
Oritavancin—Pruritus—Methylprednisolone—multiple sclerosis	0.0017	0.0017	CcSEcCtD
Oritavancin—Myalgia—Methotrexate—multiple sclerosis	0.00166	0.00166	CcSEcCtD
Oritavancin—Rash—Prednisolone—multiple sclerosis	0.00165	0.00165	CcSEcCtD
Oritavancin—Dermatitis—Prednisolone—multiple sclerosis	0.00165	0.00165	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.00165	0.00165	CcSEcCtD
Oritavancin—Diarrhoea—Methylprednisolone—multiple sclerosis	0.00165	0.00165	CcSEcCtD
Oritavancin—Headache—Prednisolone—multiple sclerosis	0.00164	0.00164	CcSEcCtD
Oritavancin—Dizziness—Triamcinolone—multiple sclerosis	0.00159	0.00159	CcSEcCtD
Oritavancin—Dizziness—Methylprednisolone—multiple sclerosis	0.00159	0.00159	CcSEcCtD
Oritavancin—Infection—Methotrexate—multiple sclerosis	0.00158	0.00158	CcSEcCtD
Oritavancin—Nervous system disorder—Methotrexate—multiple sclerosis	0.00156	0.00156	CcSEcCtD
Oritavancin—Nausea—Prednisolone—multiple sclerosis	0.00156	0.00156	CcSEcCtD
Oritavancin—Pruritus—Betamethasone—multiple sclerosis	0.00155	0.00155	CcSEcCtD
Oritavancin—Pruritus—Dexamethasone—multiple sclerosis	0.00155	0.00155	CcSEcCtD
Oritavancin—Skin disorder—Methotrexate—multiple sclerosis	0.00155	0.00155	CcSEcCtD
Oritavancin—Vomiting—Triamcinolone—multiple sclerosis	0.00153	0.00153	CcSEcCtD
Oritavancin—Vomiting—Methylprednisolone—multiple sclerosis	0.00153	0.00153	CcSEcCtD
Oritavancin—Rash—Triamcinolone—multiple sclerosis	0.00152	0.00152	CcSEcCtD
Oritavancin—Dermatitis—Triamcinolone—multiple sclerosis	0.00152	0.00152	CcSEcCtD
Oritavancin—Rash—Methylprednisolone—multiple sclerosis	0.00152	0.00152	CcSEcCtD
Oritavancin—Dermatitis—Methylprednisolone—multiple sclerosis	0.00152	0.00152	CcSEcCtD
Oritavancin—Urticaria—Prednisone—multiple sclerosis	0.00151	0.00151	CcSEcCtD
Oritavancin—Headache—Triamcinolone—multiple sclerosis	0.00151	0.00151	CcSEcCtD
Oritavancin—Headache—Methylprednisolone—multiple sclerosis	0.00151	0.00151	CcSEcCtD
Oritavancin—Diarrhoea—Dexamethasone—multiple sclerosis	0.0015	0.0015	CcSEcCtD
Oritavancin—Diarrhoea—Betamethasone—multiple sclerosis	0.0015	0.0015	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.00145	0.00145	CcSEcCtD
Oritavancin—Dizziness—Dexamethasone—multiple sclerosis	0.00145	0.00145	CcSEcCtD
Oritavancin—Dizziness—Betamethasone—multiple sclerosis	0.00145	0.00145	CcSEcCtD
Oritavancin—Nausea—Triamcinolone—multiple sclerosis	0.00143	0.00143	CcSEcCtD
Oritavancin—Nausea—Methylprednisolone—multiple sclerosis	0.00143	0.00143	CcSEcCtD
Oritavancin—Hypersensitivity—Prednisone—multiple sclerosis	0.0014	0.0014	CcSEcCtD
Oritavancin—Vomiting—Betamethasone—multiple sclerosis	0.00139	0.00139	CcSEcCtD
Oritavancin—Vomiting—Dexamethasone—multiple sclerosis	0.00139	0.00139	CcSEcCtD
Oritavancin—Rash—Betamethasone—multiple sclerosis	0.00138	0.00138	CcSEcCtD
Oritavancin—Rash—Dexamethasone—multiple sclerosis	0.00138	0.00138	CcSEcCtD
Oritavancin—Dermatitis—Dexamethasone—multiple sclerosis	0.00138	0.00138	CcSEcCtD
Oritavancin—Dermatitis—Betamethasone—multiple sclerosis	0.00138	0.00138	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.00137	0.00137	CcSEcCtD
Oritavancin—Headache—Betamethasone—multiple sclerosis	0.00137	0.00137	CcSEcCtD
Oritavancin—Headache—Dexamethasone—multiple sclerosis	0.00137	0.00137	CcSEcCtD
Oritavancin—Pruritus—Prednisone—multiple sclerosis	0.00135	0.00135	CcSEcCtD
Oritavancin—Diarrhoea—Prednisone—multiple sclerosis	0.0013	0.0013	CcSEcCtD
Oritavancin—Nausea—Dexamethasone—multiple sclerosis	0.0013	0.0013	CcSEcCtD
Oritavancin—Nausea—Betamethasone—multiple sclerosis	0.0013	0.0013	CcSEcCtD
Oritavancin—Urticaria—Methotrexate—multiple sclerosis	0.00127	0.00127	CcSEcCtD
Oritavancin—Dizziness—Prednisone—multiple sclerosis	0.00126	0.00126	CcSEcCtD
Oritavancin—Vomiting—Prednisone—multiple sclerosis	0.00121	0.00121	CcSEcCtD
Oritavancin—Rash—Prednisone—multiple sclerosis	0.0012	0.0012	CcSEcCtD
Oritavancin—Dermatitis—Prednisone—multiple sclerosis	0.0012	0.0012	CcSEcCtD
Oritavancin—Headache—Prednisone—multiple sclerosis	0.00119	0.00119	CcSEcCtD
Oritavancin—Hypersensitivity—Methotrexate—multiple sclerosis	0.00117	0.00117	CcSEcCtD
Oritavancin—Nausea—Prednisone—multiple sclerosis	0.00113	0.00113	CcSEcCtD
Oritavancin—Pruritus—Methotrexate—multiple sclerosis	0.00113	0.00113	CcSEcCtD
Oritavancin—Diarrhoea—Methotrexate—multiple sclerosis	0.00109	0.00109	CcSEcCtD
Oritavancin—Dizziness—Methotrexate—multiple sclerosis	0.00105	0.00105	CcSEcCtD
Oritavancin—Vomiting—Methotrexate—multiple sclerosis	0.00101	0.00101	CcSEcCtD
Oritavancin—Rash—Methotrexate—multiple sclerosis	0.001	0.001	CcSEcCtD
Oritavancin—Dermatitis—Methotrexate—multiple sclerosis	0.001	0.001	CcSEcCtD
Oritavancin—Headache—Methotrexate—multiple sclerosis	0.000998	0.000998	CcSEcCtD
Oritavancin—Nausea—Methotrexate—multiple sclerosis	0.000946	0.000946	CcSEcCtD
